Bendamustine for the treatment of indolent (low grade) non-Hodgkin's lymphoma that is refractory to rituximab (terminated appraisal)

  • Technology appraisal
  • TA206
  • Published: 

History

Documents created during the development process.

Background information

Lymphoma (non-Hodgkin's) - bendamustine: provisional matrix

Lymphoma (non-Hodgkin's) - bendamustine: draft scope for consultation